116 related articles for article (PubMed ID: 32902306)
1. Health economic impact of a biopsy-based cell cycle gene expression assay in localized prostate cancer.
Gustavsen G; Taylor K; Cole D; Gullet L; Lewine N
Future Oncol; 2020 Dec; 16(36):3061-3074. PubMed ID: 32902306
[No Abstract] [Full Text] [Related]
2. Economic burden of illness associated with localized prostate cancer in the United States.
Gustavsen G; Gullet L; Cole D; Lewine N; Bishoff JT
Future Oncol; 2020 Jan; 16(1):4265-4277. PubMed ID: 31802704
[No Abstract] [Full Text] [Related]
3. The economics of active surveillance for prostate cancer.
Dall'Era MA
Curr Opin Urol; 2013 May; 23(3):278-82. PubMed ID: 23449496
[TBL] [Abstract][Full Text] [Related]
4. An economic analysis of conservative management versus active treatment for men with localized prostate cancer.
Perlroth DJ; Bhattacharya J; Goldman DP; Garber AM
J Natl Cancer Inst Monogr; 2012 Dec; 2012(45):250-7. PubMed ID: 23271781
[TBL] [Abstract][Full Text] [Related]
5. Cost-Effectiveness of Urinary Biomarker Panel in Prostate Cancer Risk Assessment.
Govers TM; Caba L; Resnick MJ
J Urol; 2018 Dec; 200(6):1221-1226. PubMed ID: 30012363
[TBL] [Abstract][Full Text] [Related]
6. A 17-Gene Genomic Prostate Score as a Predictor of Adverse Pathology in Men on Active Surveillance.
Kornberg Z; Cooperberg MR; Cowan JE; Chan JM; Shinohara K; Simko JP; Tenggara I; Carroll PR
J Urol; 2019 Oct; 202(4):702-709. PubMed ID: 31026214
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of New Tests and Interventions for Prostate Cancer Management: A Systematic Review.
Olleik G; Kassouf W; Aprikian A; Hu J; Vanhuyse M; Cury F; Peacock S; Bonnevier E; Palenius E; Dragomir A
J Natl Compr Canc Netw; 2018 Nov; 16(11):1340-1351. PubMed ID: 30442734
[No Abstract] [Full Text] [Related]
8. Utilizing time-driven activity-based costing to understand the short- and long-term costs of treating localized, low-risk prostate cancer.
Laviana AA; Ilg AM; Veruttipong D; Tan HJ; Burke MA; Niedzwiecki DR; Kupelian PA; King CR; Steinberg ML; Kundavaram CR; Kamrava M; Kaplan AL; Moriarity AK; Hsu W; Margolis DJ; Hu JC; Saigal CS
Cancer; 2016 Feb; 122(3):447-55. PubMed ID: 26524087
[TBL] [Abstract][Full Text] [Related]
9. Economic analysis of active surveillance for localized prostate cancer.
Kim S; Dall'Era MA; Evans CP
Curr Opin Urol; 2012 May; 22(3):247-53. PubMed ID: 22388666
[TBL] [Abstract][Full Text] [Related]
10. Tissue-based multigene expression tests for pretreatment prostate cancer risk assessment: current status and future perspectives.
Hiser WM; Sangiorgio V; Bollito E; Esnakula A; Feely M; Falzarano SM
Future Oncol; 2018 Dec; 14(29):3073-3083. PubMed ID: 30107751
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness Analysis of Active Surveillance Strategies for Men with Low-risk Prostate Cancer.
Sathianathen NJ; Konety BR; Alarid-Escudero F; Lawrentschuk N; Bolton DM; Kuntz KM
Eur Urol; 2019 Jun; 75(6):910-917. PubMed ID: 30425010
[TBL] [Abstract][Full Text] [Related]
12. Genomic Tests Should be Used to Help Guide Treatment of Prostate Cancer: No.
Punnen S; Parekh DJ
J Urol; 2017 Aug; 198(2):266-267. PubMed ID: 28629663
[No Abstract] [Full Text] [Related]
13. Estimating the healthcare costs of treating prostate cancer in Australia: A Markov modelling analysis.
Gordon LG; Tuffaha HW; James R; Keller AT; Lowe A; Scuffham PA; Gardiner RA
Urol Oncol; 2018 Mar; 36(3):91.e7-91.e15. PubMed ID: 29169847
[TBL] [Abstract][Full Text] [Related]
14. Genomic Strategies to Personalize Use of Androgen Deprivation Therapy With Radiotherapy.
Glicksman RM; Berlin A
Cancer J; 2020; 26(1):13-20. PubMed ID: 31977380
[TBL] [Abstract][Full Text] [Related]
15. Ability of a Genomic Classifier to Predict Metastasis and Prostate Cancer-specific Mortality after Radiation or Surgery based on Needle Biopsy Specimens.
Nguyen PL; Haddad Z; Ross AE; Martin NE; Deheshi S; Lam LLC; Chelliserry J; Tosoian JJ; Lotan TL; Spratt DE; Stoyanova RS; Punnen S; Ong K; Buerki C; Aranes M; Kolisnik T; Margrave J; Yousefi K; Choeurng V; Davicioni E; Trock BJ; Kane CJ; Pollack A; Davis JW; Feng FY; Klein EA
Eur Urol; 2017 Nov; 72(5):845-852. PubMed ID: 28528811
[TBL] [Abstract][Full Text] [Related]
16. [Economic features of active surveillance].
Huguet J; Musquera M; Ribal MJ; Alcaraz A
Arch Esp Urol; 2014 Jun; 67(5):509-13. PubMed ID: 24914850
[TBL] [Abstract][Full Text] [Related]
17. New Histopathological & Genetic Features to Improve Active Surveillance Selection for Low-Risk Prostate Cancer.
Chu K; Corcoran N; Norden S; Wong LM
Anticancer Agents Med Chem; 2018; 18(7):951-957. PubMed ID: 29141559
[TBL] [Abstract][Full Text] [Related]
18. Stability of a 17-Gene Genomic Prostate Score in Serial Testing of Men on Active Surveillance for Early Stage Prostate Cancer.
Cedars BE; Washington SL; Cowan JE; Leapman M; Tenggara I; Chan JM; Cooperberg MR; Carroll PR
J Urol; 2019 Oct; 202(4):696-701. PubMed ID: 30958742
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of a cell-cycle progression score in men with prostate cancer managed with active surveillance after MRI-guided prostate biopsy--a pilot study.
Arsov C; Jankowiak F; Hiester A; Rabenalt R; Quentin M; Schimmöller L; Blondin D; Antoch G; Albers P
Anticancer Res; 2014 May; 34(5):2459-66. PubMed ID: 24778061
[TBL] [Abstract][Full Text] [Related]
20. Comprehensive molecular classification of localized prostate adenocarcinoma reveals a tumour subtype predictive of non-aggressive disease.
Kamoun A; Cancel-Tassin G; Fromont G; Elarouci N; Armenoult L; Ayadi M; Irani J; Leroy X; Villers A; Fournier G; Doucet L; Boyault S; Brureau L; Multigner L; Diedhiou A; Roupret M; Compérat E; Blanchet P; de Reyniès A; Cussenot O
Ann Oncol; 2018 Aug; 29(8):1814-1821. PubMed ID: 29945238
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]